In 2019, ischemic heart disease caused 7.0% of all global deaths, a burden that extends beyond hospital walls. In the United States, about 375,000 people die from heart attacks each year, and most coronary heart disease deaths occur outside the hospital. This article connects major risk factors with the treatments that reduce outcomes, including guideline timing such as an immediate ECG within 10 minutes of first medical contact.
Key Takeaways
- 7.0% of all global deaths in 2019 were due to ischemic heart disease (heart attack)
- In 2019, ischemic heart disease caused 16.6% of all DALYs in low-income countries (GBD results)
- In 2021, 32.6 million U.S. adults were estimated to have heart disease (about 13.3%) (CDC Fastats)
- The Framingham Heart Study estimated that the lifetime risk of developing coronary heart disease is about 49% for men and 32% for women (lifetime probability)
- In INTERHEART, hypertension was associated with about a 2.0-fold increased odds of myocardial infarction
- ~375,000 heart-attack deaths occur in the United States each year (within broader heart disease mortality)
- Primary percutaneous coronary intervention (PCI) is recommended over fibrinolysis when it can be performed within 120 minutes of first medical contact (timing threshold)
- In NSTEMI/UA, early risk stratification and treatment within recommended time windows improves outcomes; the ACC/AHA guideline emphasizes immediate ECG within 10 minutes of first medical contact
- Median time from symptom onset to hospital arrival for myocardial infarction patients is often reported around 3–4 hours in contemporary surveys, delaying definitive treatment (publicly summarized in AHA statistics and reviews)
Heart attacks cause millions of deaths yearly, and faster treatment plus proven prevention like statins saves lives.
Related reading
01 · Category
Global Burden2 stats
01
7.0% of all global deaths in 2019 were due to ischemic heart disease (heart attack)
02
In 2019, ischemic heart disease caused 16.6% of all DALYs in low-income countries (GBD results)
Interpretation
Global Burden Interpretation
From the global burden perspective, ischemic heart disease accounted for 7.0% of all deaths worldwide in 2019 and was responsible for a much larger 16.6% of all DALYs in low income countries, highlighting a disproportionate impact on health loss where resources are limited.
02 · Category
Risk Factors & Outcomes5 stats
01
In 2021, 32.6 million U.S. adults were estimated to have heart disease (about 13.3%) (CDC Fastats)
02
The Framingham Heart Study estimated that the lifetime risk of developing coronary heart disease is about 49% for men and 32% for women (lifetime probability)
03
In INTERHEART, hypertension was associated with about a 2.0-fold increased odds of myocardial infarction
04
A 2022 systematic review found that aspirin reduced serious vascular events by about 25% (relative risk reduction) in people at increased cardiovascular risk
05
A 2020 meta-analysis reported that smoking cessation after myocardial infarction reduced the risk of recurrent MI by 36% (relative risk reduction)
Interpretation
Risk Factors & Outcomes Interpretation
Across these Risk Factors & Outcomes data, major modifiable risks and preventive actions move outcomes measurably, with hypertension roughly doubling myocardial infarction odds and smoking cessation after a heart attack cutting recurrent MI risk by 36%.
More related reading
03 · Category
Incidence & Prevalence1 stats
01
~375,000 heart-attack deaths occur in the United States each year (within broader heart disease mortality)
Interpretation
Incidence & Prevalence Interpretation
In the United States, about 375,000 people die each year from heart attacks, highlighting how the incidence and prevalence of this event translate into a major and ongoing burden even within broader heart disease mortality.
04 · Category
Treatment & Care16 stats
01
Primary percutaneous coronary intervention (PCI) is recommended over fibrinolysis when it can be performed within 120 minutes of first medical contact (timing threshold)
02
In NSTEMI/UA, early risk stratification and treatment within recommended time windows improves outcomes; the ACC/AHA guideline emphasizes immediate ECG within 10 minutes of first medical contact
03
Median time from symptom onset to hospital arrival for myocardial infarction patients is often reported around 3–4 hours in contemporary surveys, delaying definitive treatment (publicly summarized in AHA statistics and reviews)
04
In a large randomized trial, high-intensity statin therapy reduced recurrent cardiovascular events by about 15% compared with moderate-intensity statin therapy (relative risk reduction)
05
In the CURE trial, dual antiplatelet therapy (clopidogrel plus aspirin) reduced the risk of cardiovascular death, MI, or stroke by 20% relative to aspirin alone
06
In the PLATO trial, ticagrelor reduced the primary composite outcome (CV death, MI, or stroke) by 16% relative to clopidogrel in ACS
07
In the TRITON-TIMI 38 trial, prasugrel reduced the risk of the primary composite endpoint by 19% relative to clopidogrel in ACS
08
In the DAPT trial, extended dual antiplatelet therapy reduced stent thrombosis by 71% but increased moderate/severe bleeding (trade-off quantified in the publication)
09
In the ISCHEMIA trial, an initial invasive strategy did not reduce the primary outcome compared with conservative therapy over a median of about 3.2 years (hazard ratio reported in study)
10
In the SHOCK trial-era evidence, early revascularization for cardiogenic shock improved survival versus medical therapy; 30-day survival increased from about 18% to about 47% in the interventional arm (trial results)
11
In the GUSTO-1 trial, accelerated tPA plus heparin achieved 30-day mortality of about 6.3% versus 8.2% with alternative regimens (mortality comparison)
12
In the large-scale AMI registry analyses, guideline-recommended beta-blocker use after MI is associated with improved 1-year survival; meta-analyses commonly show ~20% relative reduction in mortality (quantified in clinical reviews)
13
In the AHA/ACC/CDC 2023 guidelines summary for secondary prevention, statins are recommended for nearly all patients with clinical ASCVD (percentage not applicable; timing/benefit is quantified in clinical trials) — randomized evidence shows ~25% relative reduction in major vascular events per 39 mg/dL LDL reduction
14
10% of people with symptoms of acute coronary syndrome will develop out-of-hospital cardiac arrest, emphasizing emergency response needs (ACS/AMI arrest risk summarized in clinical guidance literature)
15
In the American Heart Association 2023 statistical update, 62% of adults who die from coronary heart disease die outside the hospital (place of death distribution)
16
In 2022 in the United States, EMS systems responded to suspected cardiac events with rapid dispatch; national quality programs target first ECG within 10 minutes (performance metric cited by AHA)
Interpretation
Treatment & Care Interpretation
Treatment outcomes in heart attack care are clearly improved when evidence-based timelines and intensive therapies are followed, with faster reperfusion within 120 minutes and early guideline-directed risk treatment linked to better results, while dual antiplatelet therapy and high-intensity lipid lowering each cut key recurrent event risks by about 15 to 20% in major trials.
report visual · Comparison
Heart attack burden & risk: how common and why it matters
Ischemic heart disease accounts for a sizable share of global deaths and disability, and multiple risk factors and treatments are tied to meaningful risk changes.
~375,000 heart-attack deaths occur in the United States each year (within broader heart disease mortality)375,000
In 2019, ischemic heart disease caused 16.6% of all DALYs in low-income countries (GBD results)
16.6%
In 2021, 32.6 million U.S. adults were estimated to have heart disease (about 13.3%) (CDC Fastats)
13.3%
7.0% of all global deaths in 2019 were due to ischemic heart disease (heart attack)
7%
source-verifiedwho.int · vizhub.healthdata.org · cdc.gov · heart.org2021
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Heart Attack Statistics. Gitnux. https://gitnux.org/heart-attack-statistics
MLA
Samuel Norberg. "Heart Attack Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/heart-attack-statistics.
Chicago
Samuel Norberg. 2026. "Heart Attack Statistics." Gitnux. https://gitnux.org/heart-attack-statistics.
Sources & references
24 datasets cited across this report · attribution is report-level
+15 additional datasets cited (not shown individually)